Advanced Adult Primary Liver Cancer Clinical Trial
Official title:
A Phase II Trial of Bortezomib Plus Doxorubicin in Hepatocellular Carcinoma
This phase II trial is studying how well giving doxorubicin together with bortezomib works in treating patients with liver cancer. Drugs used in chemotherapy, such as doxorubicin, work in different ways to stop tumor cells from dividing so they stop growing or die. Bortezomib may stop the growth of tumor cells by blocking the enzymes necessary for their growth. Giving doxorubicin together with bortezomib may kill more tumor cells.
Status | Completed |
Enrollment | 42 |
Est. completion date | August 2012 |
Est. primary completion date | February 2011 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: - Patients must have microscopically confirmed hepatocellular carcinoma not amenable to curative resection; if patients have an isolated lesion in one lobe of the liver, a liver surgeon should determine resectability; central review is not required - Patients must have measurable disease as determined by Response Evaluation Criteria In Solid Tumors (RECIST) criteria, amenable to biopsy; patients are not mandated to allow biopsy, even though it is an important aspect of this clinical trial - Patients with history of malignancy treated within the past 5 years are not eligible; history of carcinoma-in-situ of cervix, squamous cell cancer of skin, basal cell cancer of skin, previously treated are allowed; others are excluded as recurrence of disease may confuse response rate and/or survival endpoints - Patients must have Eastern Cooperative Oncology Group (ECOG) performance status of 0-2 - Patients must not have had prior systemic chemotherapy for HCC; patients on antineoplastics for non-malignant diseases, such as methotrexate for rheumatoid arthritis, are allowed, providing patients have been off these agents for at least 4 weeks and all related toxicities have resolved to baseline - Patients may have had prior embolization without chemotherapy; patients who have had chemoembolization are not eligible; patients may have had radiofrequency (RF) ablation, cryosurgery or ethanol injection; patients must have documented progression with the involved lesion or at least one previously untreated lesion amenable to biopsy - Platelet count must be >= 100,000/mm^3 in absence of splenomegaly; platelet count must be >= 75,000/mm^3 with splenomegaly - Absolute neutrophil count (ANC) must be >= 1,500/mm^3 in absence of splenomegaly; ANC must be =< 1,000/mm^3 with splenomegaly - Alkaline phosphate (ALT) must be =< 5 x institutional upper limit of normal (ULN) - Aspartate aminotransferase (AST) must be =< 5 x institutional ULN - Bilirubin must be =< 2 mg/dl - Patients may not exhibit Child Pugh scale grade C cirrhosis - Serum creatinine=< 2.0 mg/dl - All females of childbearing potential must have a blood test or urine study within 2 weeks prior to registration to rule out pregnancy - Women of childbearing potential and sexually active males are strongly advised to use an accepted and effective method of contraception - Patients must not have known bleeding diathesis, international normalized ratio (INR) > 1.5 or Partial thromboplastin time (PTT) > 1.5 x institutional ULN (required due to biopsy portion of study); use of vitamin K or fresh frozen plasma to correct values just prior to biopsy or enrollment is not allowed are not eligible Exclusion criteria: - Patients have baseline peripheral neuropathy > grade 1 - Patients with history of untreated malignancy other than HCC - Patients have had prior use of octreotide or tamoxifen as therapy for HCC - Patients with known allergy to boron, mannitol or bortezomib - Women are pregnant or breast-feeding (due to the uncertain effects of bortezomib in the developing fetus and young infants) - Patients have an underlying medical condition that precludes safe participation in this clinical trial - Patients have psychiatric illness or continued substance abuse that may impair the ability to provide informed consent or prevent safe administration of bortezomib - Patients with ejection fraction (EF) < 50% measured by Echocardiography (ECHO) or Multiple gated acquisition (MUGA) - Patients on verapamil who cannot be switched to an alternative medication (due to the interaction with doxorubicin) |
Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
United States | Eastern Cooperative Oncology Group | Boston | Massachusetts |
Lead Sponsor | Collaborator |
---|---|
National Cancer Institute (NCI) |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Objective Response Rate Measured by Response Evaluation Criteria In Solid Tumors (RECIST) | Tumor response was measured by Response Evaluation Criteria In Solid Tumors (RECIST) v1.0. Objective response rate included complete response (disappearance of all tumor lesions) and partial response (At least a 30% decrease in the sum of the longest diameters of target lesions, taking as reference the baseline sum longest diameter.). | assessed every 3 cycles while on treatment. After discontinuing treatment, assessed every 3 months for 2 years and then every 6 months for 1 year | No |
Secondary | Overall Survival | Overall survival is defined as time from registration to death from any cause. Patients alive were censored at follow up. Analysis was conducted in the 38 eligible and treated patients. | assessed every 3 months for 2 years and then every 6 months for 1 year | No |
Secondary | Progression Free Survival | Time from registration to disease progression or death, whichever occurred earlier. Patients alive and progression-free were censored at last follow up. 36 eligible and treated patients were included in the analysis. The other 2 eligible and treated patients had no disease status information. | assessed every 3 cycles while on treatment. After discontinuing treatment, assessed every 3 months for 2 years and then every 6 months for 1 year. | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Terminated |
NCT00787787 -
Sunitinib Malate and Capecitabine in Treating Patients With Unresectable or Metastatic Liver Cancer
|
Phase 2 | |
Completed |
NCT00052364 -
Oxaliplatin in Treating Patients With Liver Cancer
|
Phase 2 | |
Completed |
NCT01229111 -
Cediranib Maleate and Combination Chemotherapy in Treating Patients With Advanced Biliary Cancers
|
Phase 2 | |
Completed |
NCT00107536 -
Lapatinib Ditosylate in Treating Patients With Unresectable Liver or Biliary Tract Cancer
|
Phase 2 | |
Completed |
NCT02072356 -
Radiolabeled Glass Beads in Treating Patients With Liver Cancer That Cannot be Removed by Surgery
|
Early Phase 1 | |
Completed |
NCT00604721 -
Selumetinib in Treating Patients With Locally Advanced or Metastatic Liver Cancer
|
Phase 2 | |
Completed |
NCT00101036 -
Lapatinib in Treating Patients With Locally Advanced or Metastatic Biliary Tract or Liver Cancer That Cannot Be Removed By Surgery
|
Phase 2 | |
Completed |
NCT00028496 -
Vaccine Therapy With or Without Sargramostim in Treating Patients With Advanced or Metastatic Cancer
|
Phase 1 | |
Completed |
NCT01766219 -
CPI-613 in Treating Patients With Advanced or Metastatic Bile Duct Cancer That Cannot Be Removed By Surgery
|
Phase 1/Phase 2 | |
Terminated |
NCT00427973 -
AZD2171 in Treating Patients With Locally Advanced Unresectable or Metastatic Liver Cancer
|
Phase 2 | |
Completed |
NCT00321594 -
Belinostat in Treating Patients With Liver Cancer That Cannot Be Removed By Surgery
|
Phase 1/Phase 2 | |
Terminated |
NCT00087191 -
EF5 and Motexafin Lutetium in Detecting Tumor Cells in Patients With Abdominal or Non-Small Cell Lung Cancer
|
N/A | |
Completed |
NCT00006016 -
Thalidomide and Chemoembolization With Doxorubicin in Treating Patients With Liver Cancer That Cannot be Removed by Surgery
|
Phase 2 | |
Completed |
NCT01643499 -
Genotype-guided Dosing of mFOLFIRINOX Chemotherapy in Patients With Previously Untreated Advanced Gastrointestinal Malignancies
|
Phase 1 | |
Completed |
NCT00639509 -
IMC-A12 in Treating Patients With Advanced Liver Cancer
|
Phase 2 | |
Completed |
NCT00033462 -
Erlotinib in Treating Patients With Unresectable Liver, Bile Duct, or Gallbladder Cancer
|
Phase 2 | |
Completed |
NCT01666756 -
Chinese Herbal Formulation PHY906 and Sorafenib Tosylate in Treating Patients With Advanced Liver Cancer
|
Phase 1 | |
Active, not recruiting |
NCT02119065 -
Pilot Study to Assess Lung Shunting of Yttrium-90 Microspheres Using PET/CT
|
||
Recruiting |
NCT02557503 -
Hepatic Arterial Infusion of Oxaliplatin and Fluorouracil Treatment of Advanced Primary Liver Cancer After TACE
|
Phase 4 | |
Withdrawn |
NCT01859182 -
Selumetinib and Akt Inhibitor MK-2206 in Treating Patients With Refractory or Advanced Gallbladder or Bile Duct Cancer That Cannot Be Removed By Surgery
|
Phase 2 |